Kyrexa
Kyrexa is developing the world's first oral immunotherapy for canine cancer, with a mission to make cancer care kinder. The company is addressing a growing veterinary oncology market where many dogs diagnosed with cancer currently receive no advanced treatment, while many novel therapies remain costly and require specialist care. Its lead drug, Rimcazole, is an oral small molecule designed to target cancer while sparing normal tissues and avoiding the side effects associated with traditional treatments.
Kyrexa was co-founded by a specialist vet and a physician scientist who recognised the potential for a different approach to cancer treatment. Rimcazole brings together direct anti-tumour effects, anti-angiogenic activity and immune engagement in a single oral treatment, offering potential advantages over biologic therapies.
Early pilot data from 30 dogs with advanced cancers has shown clear tumour responses while maintaining a high quality of life. Kyrexa has a patent application published with broad claims across veterinary and human oncology, providing the company with opportunities beyond its initial canine cancer application.
The company has built a lean team supported by expertise across veterinary oncology, translational cancer biology, animal health pharmaceutical product development, regulatory strategy, clinical trial execution, manufacturing, business development and commercialisation. Kyrexa has a pathway towards US FDA conditional approval by 2030, with plans to expand into wider markets beyond that. MUMS designations have recently been granted in two cancer indications, marking a major regulatory milestone.
Website: Kyrexa |